bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas

Silvano Bosari, Laura Moneghini, Daniela Graziani, Arthur K C Lee, John J. Murray, Guido Coggi, Giuseppe Viale

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

The bcl-2 gene is an oncogene that inhibits programmed cell death (apoptosis). We investigated by immunocytochemistry bcl-2 expression in normal colonic mucosa, hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel. The purpose of the investigation was twofold: to assess the possible role of bcl-2 in colorectal tumorigenesis and to evaluate its clinical significance. The cases studied included 24 hyperplastic polyps, 49 adenomas, and 205 colorectal carcinomas. In both normal mucosa and hyperplastic polyps bcl-2 immunoreactivity was detected only in the proliferative cells of the colonic crypts. Conversely, bcl-2 immunoreactivity was noted in all adenomas irrespective of the degree of dysplastic change; it was diffuse in 84% of adenomas and focal in the remaining cases. In colorectal carcinomas bcl-2 expression was undetectable in 50% and focal (less than 50% immunostained neoplastic cells) in 38% of tumors. The remaining 12% of the carcinomas displayed diffuse (more than 50% immunostained neoplastic cells) bcl-2 immunoreactivity. In colorectal carcinomas bcl-2 expression was not correlated with relevant clinicopathologic parameters, including disease stage, tumor location and growth fraction, DNA ploidy, and p53 protein accumulation, and had no prognostic significance by univariate or multivariate analysis. These results suggest that bcl-2 oncoprotein may play a role in colorectal tumorigenesis, probably in the early phases of the adenomacarcinoma sequence. bcl-2 expression in established tumors has no prognostic significance.

Original languageEnglish
Pages (from-to)534-540
Number of pages7
JournalHuman Pathology
Volume26
Issue number5
DOIs
Publication statusPublished - 1995

Fingerprint

Oncogene Proteins
Polyps
Adenoma
Adenocarcinoma
Colorectal Neoplasms
Carcinogenesis
Mucous Membrane
bcl-2 Genes
Neoplasms
Ploidies
Oncogenes
Cell Death
Multivariate Analysis
Immunohistochemistry
Apoptosis
Carcinoma
DNA
Growth
Proteins

Keywords

  • bcl-2 oncoprotein
  • colorectal adenocarcinomas
  • colorectal adenomas
  • hyperplastic polyps
  • prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. / Bosari, Silvano; Moneghini, Laura; Graziani, Daniela; Lee, Arthur K C; Murray, John J.; Coggi, Guido; Viale, Giuseppe.

In: Human Pathology, Vol. 26, No. 5, 1995, p. 534-540.

Research output: Contribution to journalArticle

Bosari, Silvano ; Moneghini, Laura ; Graziani, Daniela ; Lee, Arthur K C ; Murray, John J. ; Coggi, Guido ; Viale, Giuseppe. / bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. In: Human Pathology. 1995 ; Vol. 26, No. 5. pp. 534-540.
@article{e6318c07cecb4a5584960d4591526c75,
title = "bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas",
abstract = "The bcl-2 gene is an oncogene that inhibits programmed cell death (apoptosis). We investigated by immunocytochemistry bcl-2 expression in normal colonic mucosa, hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel. The purpose of the investigation was twofold: to assess the possible role of bcl-2 in colorectal tumorigenesis and to evaluate its clinical significance. The cases studied included 24 hyperplastic polyps, 49 adenomas, and 205 colorectal carcinomas. In both normal mucosa and hyperplastic polyps bcl-2 immunoreactivity was detected only in the proliferative cells of the colonic crypts. Conversely, bcl-2 immunoreactivity was noted in all adenomas irrespective of the degree of dysplastic change; it was diffuse in 84{\%} of adenomas and focal in the remaining cases. In colorectal carcinomas bcl-2 expression was undetectable in 50{\%} and focal (less than 50{\%} immunostained neoplastic cells) in 38{\%} of tumors. The remaining 12{\%} of the carcinomas displayed diffuse (more than 50{\%} immunostained neoplastic cells) bcl-2 immunoreactivity. In colorectal carcinomas bcl-2 expression was not correlated with relevant clinicopathologic parameters, including disease stage, tumor location and growth fraction, DNA ploidy, and p53 protein accumulation, and had no prognostic significance by univariate or multivariate analysis. These results suggest that bcl-2 oncoprotein may play a role in colorectal tumorigenesis, probably in the early phases of the adenomacarcinoma sequence. bcl-2 expression in established tumors has no prognostic significance.",
keywords = "bcl-2 oncoprotein, colorectal adenocarcinomas, colorectal adenomas, hyperplastic polyps, prognosis",
author = "Silvano Bosari and Laura Moneghini and Daniela Graziani and Lee, {Arthur K C} and Murray, {John J.} and Guido Coggi and Giuseppe Viale",
year = "1995",
doi = "10.1016/0046-8177(95)90250-3",
language = "English",
volume = "26",
pages = "534--540",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas

AU - Bosari, Silvano

AU - Moneghini, Laura

AU - Graziani, Daniela

AU - Lee, Arthur K C

AU - Murray, John J.

AU - Coggi, Guido

AU - Viale, Giuseppe

PY - 1995

Y1 - 1995

N2 - The bcl-2 gene is an oncogene that inhibits programmed cell death (apoptosis). We investigated by immunocytochemistry bcl-2 expression in normal colonic mucosa, hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel. The purpose of the investigation was twofold: to assess the possible role of bcl-2 in colorectal tumorigenesis and to evaluate its clinical significance. The cases studied included 24 hyperplastic polyps, 49 adenomas, and 205 colorectal carcinomas. In both normal mucosa and hyperplastic polyps bcl-2 immunoreactivity was detected only in the proliferative cells of the colonic crypts. Conversely, bcl-2 immunoreactivity was noted in all adenomas irrespective of the degree of dysplastic change; it was diffuse in 84% of adenomas and focal in the remaining cases. In colorectal carcinomas bcl-2 expression was undetectable in 50% and focal (less than 50% immunostained neoplastic cells) in 38% of tumors. The remaining 12% of the carcinomas displayed diffuse (more than 50% immunostained neoplastic cells) bcl-2 immunoreactivity. In colorectal carcinomas bcl-2 expression was not correlated with relevant clinicopathologic parameters, including disease stage, tumor location and growth fraction, DNA ploidy, and p53 protein accumulation, and had no prognostic significance by univariate or multivariate analysis. These results suggest that bcl-2 oncoprotein may play a role in colorectal tumorigenesis, probably in the early phases of the adenomacarcinoma sequence. bcl-2 expression in established tumors has no prognostic significance.

AB - The bcl-2 gene is an oncogene that inhibits programmed cell death (apoptosis). We investigated by immunocytochemistry bcl-2 expression in normal colonic mucosa, hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel. The purpose of the investigation was twofold: to assess the possible role of bcl-2 in colorectal tumorigenesis and to evaluate its clinical significance. The cases studied included 24 hyperplastic polyps, 49 adenomas, and 205 colorectal carcinomas. In both normal mucosa and hyperplastic polyps bcl-2 immunoreactivity was detected only in the proliferative cells of the colonic crypts. Conversely, bcl-2 immunoreactivity was noted in all adenomas irrespective of the degree of dysplastic change; it was diffuse in 84% of adenomas and focal in the remaining cases. In colorectal carcinomas bcl-2 expression was undetectable in 50% and focal (less than 50% immunostained neoplastic cells) in 38% of tumors. The remaining 12% of the carcinomas displayed diffuse (more than 50% immunostained neoplastic cells) bcl-2 immunoreactivity. In colorectal carcinomas bcl-2 expression was not correlated with relevant clinicopathologic parameters, including disease stage, tumor location and growth fraction, DNA ploidy, and p53 protein accumulation, and had no prognostic significance by univariate or multivariate analysis. These results suggest that bcl-2 oncoprotein may play a role in colorectal tumorigenesis, probably in the early phases of the adenomacarcinoma sequence. bcl-2 expression in established tumors has no prognostic significance.

KW - bcl-2 oncoprotein

KW - colorectal adenocarcinomas

KW - colorectal adenomas

KW - hyperplastic polyps

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=0028989844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028989844&partnerID=8YFLogxK

U2 - 10.1016/0046-8177(95)90250-3

DO - 10.1016/0046-8177(95)90250-3

M3 - Article

C2 - 7750937

AN - SCOPUS:0028989844

VL - 26

SP - 534

EP - 540

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 5

ER -